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Abstract
severe  infections  with  multiresistant  bacteria  (MRB)
are a medical challenge and a financial burden for hos-
pitals. the adequate antibiotic therapy is a key issue in
multiresistant bacteria management. several major cost
drivers have been identified. Remarkably drug acquisi-
tion costs are not necessarily included. Most signifi-
cant are the length of stay in hospital, the hours of
mechanical ventilation and the time treated on an in-
tensive care unit.
In a systematic review of the literature the follow-
ing aspects were investigated:
- do generic treatment strategies contribute in cost
savings?
- are there specific results for recent antibiotics?
Early  adequate  and  effective  antimicrobial  treat-
ment, switch from i.v. to oral therapy, adjusted dura-
tion of therapy and adherence to guidelines have been
found to be successful strategies.
looking at specific antibiotics, the best evidence for
cost-effectiveness is found for linezolid in treatment
of csstI as well as in HaP. daptomycin shows good
economic results in bloodstream infections, so possi-
bly  being  a  cost-effective  alternative  to  vancomycin.
looking at tigecycline the published data show neither
higher  costs  nor  savings  compared  to  imipeneme.
doripenem as one of the newest therapy options has
proven to be highly cost-saving in HaP when com-
pared  with  imipenem.  However,  most  analyses  are
based  on  pharmacoeconomic  modelling  rather  than
on directly analysing trial data or real life clinical popu-
lations.
Conclusion: using modern antibiotics in whole is not
more expensive than using established therapies. Mod-
ern antibiotics are cost-effective and sometimes even
cost-saving. this is especially true if an effective thera-
py is initiated as early as possible.
abbreviations:
alos = average length of stay in a given dRG, basis
for determining whether a patient causes more costs
than reimbursement
caP = community acquired pneumonia
csstI = complicated skin and soft tissue infections
dRG = diagnoses related groups, systems to classify
patients based on their resource consumptions
HaP = hospital acquired pneumonia
HMV = hours of mechanical ventilation
Icu-days = treatment days on an intensive care unit
los = length of stay in hospital
MRB = infection with Multiresistant bacteria
IntRoductIon
severe MRB cause a serious burden of disease in most
countries  worldwide  [1,  2,  6,  23].  their  therapeutic
management is a major cost driver in healthcare , par-
ticularly in hospitals. looking at the economical im-
pact of antibiotic therapy of severe MRB infections,
several factors were identified as the major cost drivers
[3-5]:
- prolonged hospital length of stay (los)
- hours of mechanical ventilation (HMV)
-  duration  of  treatment  on  an  intensive  care  unit
(Icu)
- cost of patient isolation (isolation)
-  complications,  such  as  renal  failure  or  infection
transmission
Whether any given antibiotic therapy is an econom-
ically adequate option therefore depends on its effect
on one or more of these cost drivers. Interestingly, the
actual daily costs of the drug itself does not signifi-
cantly  affect  the  overall  costs  of  treatment.  still  in
many settings, the choice of therapy is controlled by
drug acquisition costs, as these data are easily available
[7, 8].
this article provides a review of the current litera-
ture on the role of recent antibiotic agents in the treat-
ment  of  MRB  infections  from  the  economical  per-
spective.
MatERIals and MEtHods
We  conducted  a  literature  review  to  investigate  the
available evidence on cost-effectiveness of antibiotic
treatment strategies in the management of MRB infec-
tions. looking at the economical impact of antibiotic
therapy in general, there are the following factors that
have been proven to influence positively the above-
mentioned cost drivers:
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Influencing factor Effect on cost driver Ref.
Early adequate first-line antibiotic therapy shorter duration of therapy
Early transfer from Icu to normal ward
shorter los
less complications [9-13]
IV-to-oral switch shorter i.v. therapy 
Earlier discharge and outpatient treatment [14-17]
adjusted duration of therapy less adverse events
less selection of resistance
less drug cost
shorter los [18-22]
adherence to guidelines shorter duration of therapy
shorter los 
less complications
less Icu admissions
less HMV [7, 24, 25]
Fig. 1.
Fig. 2.
literature review
on  25  selected
publications  on
new antibiotics.
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cost drivers, we conducted a literature review focussed
on articles dealing with recently introduced antibiotics
active against MRB in the context of cost issues or
cost-impacting factors.
We  used  the  agent  and  ‘cost-effectiveness’  oR
‘economical’ as search terms. 
REsults
We had 178 search findings in total. figure 1 shows
the search findings.
the number of publications referring explicitely to
cost-effectiveness or economical analyses on linezolid
is the highest. for closer analysis we then picked 25 ar-
ticles that focussed on one or more of our above men-
tioned cost drivers.
In general economical analyses for drugs often dif-
fer from clinical trials. the most common method is
modelling  economical  effects  by  using  results  from
clinical trials. only rarely economical data are directly
collected in the course of clinical trials. nearly no data
exist on economical analyses based on clinical routine
treatment.
figure 2 shows the results of the 25 articles closely
reviewed.
In the following section we describe major findings
for the agents in focus.
lInEzolId
Multiple  economic  analyses  for  linezolid  have  been
published  over  the  last  decade.  there  are  publi-
cations  for  both  major  indications  (csstI,  HaP) 
and  for  several  countries  (usa,  Germany,  spain,
france).  thus  the  economics  of  linezolid  use 
effects appear to be well investigated. studies are ei-
ther  cost-effectiveness  analyses  based  on  data  of 
clinical  trials  or  pharmacoeconomic  models  [26-30].
the cost savings associated with the use of linezolid
are  predominantly  due  to  a  significant  reduction  of
los. among recent antibiotics used for MRB infec-
tion, linezolid is the only drug that is available intra-
venous (IV) and orally (with a similar dose/exposure
ratio),  and  the  IV-to-oral  switch  allows  earlier 
hospital discharge. the net effect is most significant
in the treatment of csstI (2.0 – 2.3 los days saved),
as  the  overall  severity  of  illness  is  lower  than  in 
pneumonia,  and  hospital-acquired  pneumonia  in 
particular. However, linezolid has been shown to be
cost-effective  in  pneumonia  as  well.  this  is  most 
likely due to earlier recovery and earlier hospital dis-
charge.  Most  authors  today  acknowledge  linezolid 
as a cost-effective component of the therapeutic ar-
mamentarium,  particularly  in  MRsa  infections  [32].
However,  this  insight  has  not  been  entirely  imple-
mented in clinical practice yet [33].
there are no explicit analyses available for other
cost drivers. Most recently, a meta-analysis [31] sug-
gested  that  there  is  no  specific  economic  rationale
supporting the use of vancomycin versus linezolid for
empiric  therapy  in  settings  with  low  MRsa  preva-
lence. 
daPtoMycIn
Introduced more recently than linezolid, daptomycin
already  prompted  a  substantial  number  of  publica-
tions on economic issues and publications referring to
significant cost drivers [34-40]. the most relevant in-
dication for daptomycin is bloodstream infection with
gram-positive cocci, as the overall number of patients
is significantly higher than in endocarditis. similar to
most of the other drugs discussed here, daptomycin is
also suitable for the treatment of csstI. the main
economic impact of daptomycin is associated with a
reduction  of  los.  However,  earlier  transfer  from
Icu to general ward is also described. some publica-
tions [35, 37-39] attribute lower costs to earlier cure
and higher cure rates achieved with daptomycin ver-
sus vancomycin, which may relate to the bactericidal
effect  of  the  drug.  However  the  trials  underlying
these analyses were no Rcts. 
daptomycin has been shown to be associated with
less occurrence of renal failure than vancomycin [34].
It thus may be speculated that the lipopeptide antibi-
otic has a potential to influence positively the cost-dri-
ving duration of therapy as mentioned in one publica-
tion (39). However, this aspect still awaits further in-
vestigation.  
doRIPEnEM
convincing economic analyses and articles referring to
cost drivers in clinical studies have been published for
doripenem, a recently approved carbapenem antibiotic
[41-45]. doripenem was shown to be associated with
less resource use regarding los, HMV, and less com-
plications  (Psa  resistance,  Psa  transmissions)  com-
pared to imipenem. no significant reduction in Icu
days has been described so far. Remarkably, economi-
cal evaluation of this drug was included in the data
and analysis of clinical trials. 
tIGEcyclInE
among  the  articles  retrieved  on  tigecycline  [46-51],
there were two dedicated analyses that dealt with re-
source utilization (i.e. cost) associated with the use of
this  recently  introduced  glycylcyclin  antibiotic  [49].
tigecycline is an interesting treatment option particu-
larly in complicated intraabdominal infections. With
its very broad spectrum of activity, tigecycline can be
used  empirically  in  suspected  polymicrobial  infec-
tions.  despite  the  slightly  higher  drug  acquisition
costs compared to imipenem it has been showed that
first-line  therapy  is  not  more  expensive  than  using
tigecycline in second-line therapy [51]. It also has the
potential to be used as a monotherapy in this indica-
tion [48] and therefore would affect overall costs by
abolishing the need for another drug. two publica-
tions explicitly report that los was not negatively af-
fected  when  comparing  tigecycline  with  imipenem
[49, 50]. 
table 1 summarizes the data indicating a positive
influence of the drugs covered in this review on cost
drivers and influencing factors.
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It appears that the number of publications that evalu-
ate the economic impact of new antimicrobial agents
such as linezolid, daptomycin, tigecycline and doripen-
em is increasing. for every substance there are results
or  at  least  trends  that  indicate  favourable  effects  on
economic outcomes. the studies uniformly show that
despite higher drug acquisition costs for newer antibi-
otics, overall treatment costs can be lower or therapy is
cost-effective due to other factors (i.e. survival for line-
zolid in pneumonia). only a limited number of studies
analyzed ‚real-life‘ clinical populations [11-13, 24, 27,
28, 37, 39], whereas the greater part of the publica-
tions used pharmacoeconomic models based on data
from  clinical  trials.  While  this  is  a  well-accepted  ap-
proach, it does not prove the relevance of the respec-
tive findings in the clinical routine setting. obviously, it
is a most challenging task to validate data from phar-
macoeconomic models in “real life”, as the variance of
patient characteristics is much higher than in trial pop-
ulation  and  various  confounders  complicate  such
analyses. there are some ongoing studies trying to re-
late dRG outcomes – i.e. the net effect on hospital re-
imbursement – to the chosen therapy strategies. It will
be interesting to see the results in the near future.
conclusIon
the economic impact of antibiotic treatment choices
in complicated infections with multiresistant bacteria
is an increasingly important issue, as numerous publi-
cations document the enormous extra healthcare cost
of  these  infections  (1,  3,  4,  9,  10,  13,  36,  41).  the
analysis of the current literature shows that therapy
with modern antibiotics is generally cost-effective and
may even be associated with net savings although drug
acquisition  costs  are  higher  in  conventional  therapy
regimens.  currently,  favourable  cost  effects  are  best
documented for linezolid. a number of pharmacoeco-
nomic analyses are also available for daptomycin, tige-
cyclin and doripenem, and more will certainly follow.
Investigators  may  increasingly  use  economic  data  to
document  favourable  cost  effects  of  state-of-the-art
therapy, thus overcoming the still wide-spread focus
on ‚price-tags‘.  However only a few analyses use ‘real-
life’ clinical settings for cost analyses. Modelling is the
most common and most accepted approach to gain
‘economical evidence’. With directly connecting eco-
nomical  analyses  to  clinical  trials  and/or  to  routine
data collections the results would reach a higher level
of acceptance among hospital administrators.
clinicians, pharmacists and economists in the hos-
pital should work together to realize cost-savings with
effective  antibiotic  therapy  rather  than  sticking  to
treatment choices driven by drug acquisition cost. 
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